PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF

Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF).
The EMPEROR-Preserved trial has shown Jardiance (empagliflozin) can significantly reduce the risk of cardiovascular death or hospitalisation in adults living with HFpEF, with or without diabetes.
In a statement, the two pharma companies said the results establish Jardiance as the first SGLT2 inhibitor treatment to show benefit for HFpEF patients.
“The EMPEROR-Preserved topline results represent a significant breakthrough in cardiovascular medicine and for people with heart failure, which is an increasingly prevalent public health issue affecting millions of people worldwide,” said Iain Squire, lead investigator for EMPEROR-Preserved in the UK.
“HFpEF has been the most challenging form of heart failure to treat, given the lack of evidence-based treatments up until now. The findings from EMPEROR-Preserved demonstrate the potential of Jardiance to reduce cardiovascular death or hospitalization for heart failure with preserved ejection fraction,” he added.
Following the topline results, Lilly and Boehringer will reveal full results from the EMPEROR-Preserved trial at the upcoming European Society of Cardiology (ESC) congress in August.
The companies are also planning to file Jardiance for regulatory approvals by the end of the year.
“These highly-anticipated results demonstrate the potential of Jardiance in heart failure with preserved ejection fraction which can be devastating to those affected, impacting their daily activities while posing a greater risk of other vascular complications,” said Douglas Clark, head of medical affairs for UK and Ireland at Boehringer Ingelheim.
“The BI/Lilly Alliance is committed to exploring how we can help to support these patients and developing new treatment options for their healthcare professionals,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026